| Revenue growth | FY26 consolidated ₹142 cr; India business grew 10% YoY. |
|---|---|
| Margins | Standalone EBITDA at 55%; consolidated FY26 EBITDA at 40%. |
| Order book | Coris has €2.4M remaining in HAT contract for Congo. |
| Demand visibility | Visibility from long-term reagent rentals and institutional supply programs. |
| Management confidence | High confidence in US FDA approvals and 15-20% growth guidance. |
Growth
FY26 revenue grew to ₹142 cr; 3B India molecular diagnostics grew 10% YoY to ₹86.47 cr.
Outlook
Targeting 15-20% revenue and EBITDA growth for FY27; US FDA submission for AMR products ongoing; M&A active search.
Risks
Geopolitical tensions in Middle East impacting exports; seasonality in flu/dengue demand; increased competition in low-priced assays.
Earnings Call filed with BSE, NSE: 3BBLACKBIO. Summary written with AI assistance from the document.
3B BlackBio Dx Ltd: key numbers
- Share price
- ₹1,463.50
- Market cap
- ₹1,256 Cr
- Revenue (annual)
- ₹141.9 Cr
- Net profit (annual)
- ₹58.59 Cr
- P/E (TTM)
- 22.6×Sector 37.5×
- Promoter holding
- 40.95%+0.01% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from 3B BlackBio Dx Ltd
All →3B BlackBio Dx Other Announcement
3B BlackBio Dx sent a Reg 36(1)(b) letter to shareholders providing the weblink to its FY 2025-26 Annual Report ahead of the 54th AGM. No financial figures or business events are disclosed.
3B BlackBio Dx Annual Report
3B BlackBio Dx Ltd filed its FY 2025-26 Annual Report with BSE under Regulation 34(1). The report recaps its molecular diagnostics growth and global expansion.
3B BlackBio Dx Annual General Meeting
3B BlackBio Dx Ltd issued notice for its 54th AGM on 29 September 2026. Proposed business includes FY26 financials adoption and Rs.5 per share final dividend.
3B BlackBio Dx Investor Presentation: Key Takeaways
3B BlackBio Dx reported Q1FY27 consolidated revenue of ₹33.49 Cr, up 50% YoY, driven by the Coris BioConcept acquisition. Core MDx business grew 17.4% excluding Coris.
- Call
- Guides 18% growth
3B BlackBio Dx Q1 FY27 Results: Net Profit ₹9 Cr, Down 28.6% YoY
3B BlackBio Dx Ltd reported revenue from operations of ₹33.5 Cr (+50.9% YoY) and net profit of ₹9 Cr (-28.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹9 Cr · -28.6% YoY
3B BlackBio Dx Earnings Call: Key Takeaways
3B BlackBio reported strong FY26 consolidated revenue of ₹142cr with a PAT of ₹60cr, driven by European acquisitions despite slower domestic molecular diagnostic growth.